Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd. (the "Company") is dated February 10, 2026. The report discloses the entry into a Sales Agreement with Leerink Partners LLC to establish an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new capital raising facility.
- Maximum Offering Size: Up to $50,000,000 in aggregate offering price.
- Commission Rate: 3.0% of the gross sales price of shares sold.
- Expense Reimbursement Cap: Up to $75,000 for initial transaction expenses, $25,000 per Representation Date for ongoing diligence, and $15,000 for outside legal counsel fees.
Material Changes
The material change disclosed is the execution of the Offering Agreement on February 10, 2026, enabling the Company to sell ordinary shares through Leerink Partners acting as sales agent or principal. This program is supported by a shelf registration statement on Form F-3 (File No. 333-293145) declared effective on the same date.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company is not obligated to sell any shares under the agreement. Sales may be suspended at any time by either party. The actual total offering amount, commissions, and proceeds are not determinable at this time as there is no minimum offering amount required.
Risks and Contingencies: The Company has agreed to indemnify Leerink Partners against certain liabilities, including those under the Securities Act. Sales are subject to prevailing market prices and the terms of the Offering Agreement.
Investor Verification Checklist
- Verify the current market price of OKYO Pharma Ltd. ordinary shares to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific covenants and termination rights.
- Monitor future filings for actual share sales and proceeds generated under this ATM program.
- Confirm the Company's current cash position to understand the necessity of this capital raise.